Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate
Effect of Dialysate Flow Rate on Delivered Dose of Dialysis (Kt/Vurea)
Sponsor: Baxter Healthcare Corporation
Listed as NCT00962000, this NA trial focuses on Chronic Kidney Disease and Chronic Renal Disease and remains completed. Sponsored by Baxter Healthcare Corporation, it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Aug 2025 — Present [monthly]
Completed NA
-
Apr 2025 — Aug 2025 [monthly]
Completed NA
-
Sep 2024 — Apr 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jul 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Jul 2017 [monthly]
Completed NA
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxter Healthcare Corporation
- Gambro Renal Products, Inc.
- University of California, Davis
- University of Louisville
- Vanderbilt University Medical Center
- Vantive Health LLC
For direct contact, visit the study record on ClinicalTrials.gov .